Literature DB >> 15855408

Receptor signaling and endocytosis are differentially regulated by somatostatin analogs.

Qisheng Liu1, Renzo Cescato, Dian A Dewi, Jean Rivier, Jean-Claude Reubi, Agnes Schonbrunn.   

Abstract

Upon hormone stimulation, the sst2 somatostatin receptor couples to adenylyl cyclase through G(i/o) proteins and undergoes rapid endocytosis via clathrin-coated pits. In this study, we determined the relationship between the ability of ligands to induce sst2 receptor internalization and inhibit adenylyl cyclase. Immunocytochemical studies demonstrated that peptide agonists [such as somatostatin-14, cortistatin-17, octreotide, vapreotide, KE108 (Tyr0-cyclo[d-diaminobutyric acid-Arg-Phe-Phe-d-Trp-Lys-Thr-Phe]), and SOM230 (cyclo[diaminoethylcarbamoyl-hydroxyproline-phenylglycine-d-Trp-Lys-(4-O-benzyl)-l-Tyr-Phe])] and nonpeptide agonists (such as L-779,976), stimulated the rapid endocytosis of sst2 receptors in human embryonic kidney 293 and CHO-K1 cells. In contrast, two antagonists did not induce receptor endocytosis by themselves and completely blocked agonist stimulation. Using a quantitative enzyme-linked immunosorbent assay to measure sst2 receptor sequestration, we found that peptide agonists varied by more than 100-fold in their potencies but exhibited the same efficacy as somatostatin14. In contrast, L-779,976 did not induce maximal receptor internalization. It is interesting that although betaarrestin-2 was recruited to cell surface sst2 receptors after stimulation with either somatostatin14 or L-779,976, the betaarrestin-receptor complex dissociated earlier in the endocytic pathway with the nonpeptide ligand. Although all agonists, including L-779,976, produced the same maximal inhibition of cyclic AMP, the potency ratio for inhibition of cyclic AMP and stimulation of receptor endocytosis varied by 15-fold. In general, native peptides showed similar potencies for cyclic AMP inhibition and receptor endocytosis, whereas short therapeutic analogs were substantially more potent at inhibiting cyclic AMP synthesis. These results demonstrate that the activity of somatostatin analogs to regulate receptor endocytosis and signaling are not tightly linked and provide compelling evidence for the induction of agonist specific states of the sst2 receptor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855408     DOI: 10.1124/mol.105.011767

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  36 in total

1.  Targeted entry via somatostatin receptors using a novel modified retrovirus glycoprotein that delivers genes at levels comparable to those of wild-type viral glycoproteins.

Authors:  Fang Li; Byoung Y Ryu; Robin L Krueger; Scott A Heldt; Lorraine M Albritton
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

Review 2.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

3.  Cubilin and megalin in radiation-induced renal injury with labelled somatostatin analogues: are we just dealing with the kidney?

Authors:  R Moncayo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10       Impact factor: 9.236

4.  Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients.

Authors:  Beatrice Waser; Renzo Cescato; Qisheng Liu; Yachu J Kao; Meike Körner; Emanuel Christ; Agnes Schonbrunn; Jean Claude Reubi
Journal:  Am J Pathol       Date:  2012-05       Impact factor: 4.307

5.  Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists.

Authors:  Yachu J Kao; Madhumita Ghosh; Agnes Schonbrunn
Journal:  Mol Endocrinol       Date:  2011-04-14

Review 6.  Selective agonism in somatostatin receptor signaling and regulation.

Authors:  Agnes Schonbrunn
Journal:  Mol Cell Endocrinol       Date:  2007-10-07       Impact factor: 4.102

Review 7.  Fine-tuning somatostatin receptor signalling by agonist-selective phosphorylation and dephosphorylation: IUPHAR Review 5.

Authors:  Stefan Schulz; Andreas Lehmann; Andrea Kliewer; Falko Nagel
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

8.  Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.

Authors:  Renzo Cescato; Kimberly A Loesch; Beatrice Waser; Helmut R Mäcke; Jean E Rivier; Jean Claude Reubi; Agnes Schonbrunn
Journal:  Mol Endocrinol       Date:  2009-11-12

9.  Differential temporal and spatial regulation of somatostatin receptor phosphorylation and dephosphorylation.

Authors:  Madhumita Ghosh; Agnes Schonbrunn
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

10.  Effects of chelator modifications on (68)Ga-labeled [Tyr (3)]octreotide conjugates.

Authors:  Mai Lin; Michael J Welch; Suzanne E Lapi
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.